FDA cardiovascular devices division
This article was originally published in The Gray Sheet
Executive Summary
Acting director of the office of device evaluation's division of cardiovascular, respiratory and neurological devices will be Thomas Callahan, effective July 10, FDA says. Callahan, a 15- year FDA veteran, currently is an associate director of ODE's division of general and restorative devices. He will replace Abhijit Acharya, who is leaving FDA on July 10 to join the Arlington, Virginia-based Biometric Research Institute ("The Gray Sheet" May 17, In Brief).
You may also be interested in...
How Ochre Bio Bagged Boehringer For Its RNA-Based Regenerative MASH Therapies
UK-based Ochre Bio has signed its first major deal with Boehringer Ingelheim. Scrip talked to its co-founder and CEO, Jack O’Meara, about its human tissue-based drug discovery platform, its resulting RNA platform for liver disease and how the fledgling drug company's early work mirrored that seen in diagnostics.
IGI Bets On Trispecific Antibody To Make Inroads Into Big Pharma Myeloma Turf
Ichnos Glenmark Innovation’s president and CEO talks to Scrip about the promising activity profile of the alliance’s early stage trispecific antibody versus Janssen’s teclistamab and also maintains that the setback for Gilead’s magrolimab hasn’t eclipsed prospects for its bispecific antibody.
UK Medtech Strategy Sets Out Schedule Of Milestones To FY 2026
Fourteen months on from the release of its inaugural medtech strategy, the UK MedTech Directorate has laid firm foundations and reports progress on initiatives aimed at improving technology adoption. A schedule of ambitious future timelines has also been published.